Vijaya Diagnostic Centre Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹255 Cr +26.2% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
VD

Vijaya Diagnostic Centre Ltd

Q2 FY26Healthcare Services

Vijaya Diagnostic Centre Q2 FY26: Capex ₹160 Cr

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹202Cr
+10.4% YoY
+7.4% QoQ
Net profit
₹43Cr
+2.4% YoY
+10.3% QoQ
Margin
41%
−1 pp YoY
+2 pp QoQ
Price₹1,504
Market cap₹14.3K Cr
P/E82.7

The short version

Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.

From Vijaya Diagnostic Centre Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Vijaya Diagnostic Centre targets around 15% overall year-level growth.
  • Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%.
  • Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term.
  • Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology.
  • Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier.
  • Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up.
  • Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth.

2 more points from Vijaya Diagnostic Centre Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Vijaya Diagnostic Centre Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
  • FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26.
  • CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets.
  • Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26.
  • Plans to increase hubs from current two to five by end of FY27.
  • Long-term expansion plan includes lease properties for new hubs/spokes.

2 more points from Vijaya Diagnostic Centre Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Vijaya Diagnostic Centre Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Vijaya Diagnostic Centre Ltd said on order book & pipeline — free account, 30 seconds.

Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Vijaya Diagnostic Centre Ltd Q2 FY26 results — key figures

Vijaya Diagnostic Centre Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue202183+10.4%188+7.4%
Operating profit (EBITDA)8276+7.9%74+10.8%
Operating margin41%42%-1 pp39%+2 pp
Profit before tax5857+1.8%52+11.5%
Net profit (PAT)4342+2.4%39+10.3%
EPS (₹)4.214.10+2.7%3.76+12%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹255 Cr, net profit ₹59 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Maitreya Medicare (Q2 FY26)

    23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.

  • Metropolis Healt (Q2 FY26)

    Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…

  • 3B Blackbio (Q2 FY26)

    Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…

  • Unihealth Hosp (Q2 FY26)

    Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vijaya Diagnostic Centre Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vijaya Diagnostic Centre Ltd Q2 FY26 results?

Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.

What is Vijaya Diagnostic Centre Ltd share price analysis?

Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vijaya Diagnostic Centre Ltd planning capital expenditure?

FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.

Keep Vijaya Diagnostic Centre Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.